China
Africa
Explore chapters and articles related to this topic
Introduction
Published in Mickey C. Smith, E.M. (Mick) Kolassa, Walter Steven Pray, Government, Big Pharma, and the People, 2020
Mickey C. Smith, E.M. (Mick) Kolassa, Walter Steven Pray
Whether we are ultimately to have socialized medicine in the United States will be determined to a large measure by the answers which our society finds two questions: Is health care a right? And, if so,What system of health care delivery and financing is most likely to assure this right?
The Medicalization of Death
Published in Gerry R. Cox, Neil Thompson, Death and Dying, 2020
In countries without socialized medicine, those with no insurance or government programs may simply be denied treatment because they are poor, or not a citizen of the country where they are living. Discrimination therefore affects care options. Dying people also have a right to hope! They still have a future, even if it may be a shortened one. However, the medical model is not the only one available for dying and grieving people. It has been challenged by the emergence of a public health approach.
Soviet Medicine
Published in Roger Cooter, John Pickstone, Medicine in the Twentieth Century, 2020
A central element in socialized medicine is the principle of entitlement, of a citizens’ right to a service — a claim, backed by a constitution. Socialized medicine provides an element of psychological assurance that the state not only has the duty to take care of the health of its citizens, but that it has assumed this obligation in earnest. The Soviet regime provided this assurance as part of a basket of safety-nets which the population accepted as its due.
Parents’ Experiences with Implementing Therapy Home Programs for Children with Down Syndrome: A Scoping Review
Published in Occupational Therapy In Health Care, 2020
Brandon J. Walker, Leon Washington, Diana Early, Gail A. Poskey
Four of the articles included in this scoping review were not based solely on children with DS, but instead included children with other developmental diagnoses. Therefore, clinicians should not infer that the results of this study represent the perspective of all parents of children with DS perspective. Three of the studies were performed in countries with socialized medicine. Practitioners who reside in countries with non-socialized medicine may not be able to generalize the findings included in this review. Other limitations of the present study relate to elements of the literature search: including a limited number of search terms and the small number of studies that met inclusion criteria (six). Searching more databases and using different search terms (e.g., developmental disabilities, compliance) may have yielded more articles that met inclusion criteria.
Facts and ideas from anywhere
Published in Baylor University Medical Center Proceedings, 2019
By 1960, as the medical revolution was gaining speed, the economically flawed private health care financing system was fully in place. Then two other events added to the gathering debacle. In 1965, the government entered the medical insurance market with Medicare for the elderly and Medicaid for the poor. Both physicians and hospitals fought tooth and nail to prevent what they called “socialized medicine” from gaining a foothold in the US. As a result of their strident opposition, when the two programs were finally enacted, they were structured much like Blue Cross/Blue Shield, with the government picking up much of the cost. And when Medicare and Medicaid proved a bonanza for providers, their vehement opposition faded away. The two new systems greatly increased the number of people who could afford advanced medical care and the incomes of medical professionals soared, roughly doubling in the 1960s.
The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review
Published in Expert Opinion on Biological Therapy, 2021
Khalaf Kridin, A. Razzaque Ahmed
Regardless of the marketing by the manufacturer and the publications of the authors, patients’ perspectives must be borne in mind. The drug is expensive. In the US though approved by FDA, insurance companies require detailed letters to justify its use. In countries with socialized medicine, it is similar. In the rest of the world, the patient must buy it.